Advertisement

Severe Mitral Regurgitation Treatment: Percutaneous Options, Patient Selection, and Preoperative Evaluation

  • Michele PighiEmail author
  • Anita W. Asgar
Chapter

Abstract

Mitral regurgitation (MR) is a common valvular disorder affecting millions of people in the United States and Europe. The etiology of MR can be divided into primary MR, caused by pathology of the valve apparatus, and secondary, a functional consequence of ventricular dysfunction. The clinical course of MR is generally insidious and, if left untreated, leads to heart failure and ultimately death. Despite the fact that surgery is considered the gold standard for the treatment of severe MR, over the last few years, an increasing amount of data has suggested that a substantial proportion of patients are not suitable for surgical treatment due to the presence of comorbidities, leading to poor procedural and long-term outcomes. In this context, over the last decade, the evolution of device technology has resulted in the development of less invasive interventional techniques designed to target the different components of the mitral apparatus. Due to the extreme complexity of the mitral valve (MV) and the multiple etiologies of the disease, the efficacy and the safety of many of these new techniques are still under investigation. There are currently an increasing number of devices under investigation and ongoing randomized controlled trials that demonstrate the deep interest in the percutaneous treatment of MV disease and promise an intriguing future for technology in this field.

Keywords

Mitral Valve Mitral Regurgitation Cardiac Resynchronization Therapy Coronary Sinus Mitral Annulus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol. 2014;30(9):962–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Authors/Task Force Members, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33(19):2451–96.CrossRefGoogle Scholar
  3. 3.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014. pp. e57–185.Google Scholar
  4. 4.
    Goel SS, Bajaj N, Aggarwal B, Gupta S, Poddar KL, Ige M, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63(2):185–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231–48.CrossRefPubMedGoogle Scholar
  6. 6.
    Ho SY. Anatomy of the mitral valve. Heart. 2002.Google Scholar
  7. 7.
    Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON mitral annuloplasty device European union study. Circulation. 2009;120(4):326–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2014;14(8):931–8.CrossRefGoogle Scholar
  9. 9.
    Harken DE, Ellis LB, Dexter L, Farrand RE, Dickson JF. The responsibility of the physician in the selection of patients with mitral stenosis for surgical treatment. Circulation. 1952;5(3):349–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Carpentier AF, Lessana A, Relland JYM, Belli E, Mihaileanu S, Berrebi AJ, et al. The “Physio-Ring”: an advanced concept in mitral valve annuloplasty. ATS. 1995;60(5):1177–86.Google Scholar
  11. 11.
    Shah PM. Current concepts in mitral valve prolapse – diagnosis and management. J Cardiol. 2010;56(2):125–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Alfieri O, Maisano F, De Bonis M, Stefano PL, Torracca L, Oppizzi M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg. 2001;122(4):674–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange R, Schoenburg M, et al. Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT Trial (Transapical Artificial Chordae Tendineae) proof of concept. J Am Coll Cardiol. 2014;63(9):914–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Anyanwu AC, Adams DH. Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency. Semin Thorac Cardiovasc Surg. 2007;19(2):90–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Fenster MS, Feldman MD. Mitral regurgitation: an overview. Curr Probl Cardiol. 1995;20(4):199–276.CrossRefGoogle Scholar
  16. 16.
    Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: a quantitative clinical study. Circulation [Internet]. 2000;102(12):1400–6. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=10993859&retmode=ref&cmd=prlinks.CrossRefGoogle Scholar
  17. 17.
    Chaput M, Handschumacher MD, Tournoux F, Hua L, Guerrero JL, Vlahakes GJ, et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation. 2008;118(8):845–52.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hung J. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target. Circulation. 2004;110(11_Suppl_1):II–85–90.CrossRefGoogle Scholar
  19. 19.
    Dal-Bianco JP, Levine RA. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography. Echocardiogr Diagn Manag Mitral Valve Dis. 2013;31(2):151–64.Google Scholar
  20. 20.
    Kumanohoso T, Otsuji Y, Yoshifuku S, Matsukida K, Koriyama C, Kisanuki A, et al. Mechanism of higher incidence of ischemic mitral regurgitation in patients with inferior myocardial infarction: quantitative analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial infarction. J Thorac Cardiovasc Surg. 2003;125(1):135–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Agricola E. Echocardiographic classification of chronic ischemic mitral regurgitation caused by restricted motion according to tethering pattern. Eur J Echocardiogr. 2004;5(5):326–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Nagasaki M, Nishimura S, Ohtaki E, Kasegawa H, Matsumura T, Nagayama M, et al. The echocardiographic determinants of functional mitral regurgitation differ in ischemic and non-ischemic cardiomyopathy. Int J Cardiol. 2006;108(2):171–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Carabello BA, Williams H, Gash AK, Kent R, Belber D, Maurer A, et al. Hemodynamic predictors of outcome in patients undergoing valve replacement. Circulation. 1986;74(6):1309–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Mauri L, Garg P, Massaro JM, Foster E, Glower D, Mehoudar P, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. 2010;160(1):23–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. pp. e147–239.Google Scholar
  26. 26.
    Tops LF, Van de Veire NR, Schuijf JD, de Roos A, van der Wall EE, Schalij MJ, et al. Noninvasive evaluation of coronary sinus anatomy and its relation to the mitral valve annulus: implications for percutaneous mitral annuloplasty. Circulation. 2007;115(11):1426–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Maselli D, Guarracino F, Chiaramonti F, Mangia F, Borelli G, Minzioni G. Percutaneous mitral annuloplasty: an anatomic study of human coronary sinus and its relation with mitral valve annulus and coronary arteries. Circulation. 2006;114(5):377–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Sahni D, Randhawa A, Aggarwal A, Rohit MK. Spatial relationship of coronary sinus-great cardiac vein with adjoining anatomic structures: a key element in predicting the success of percutaneous transvenous mitral annuloplasty. J Heart Valve Dis. 2014;23(2):184–92.PubMedGoogle Scholar
  29. 29.
    Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, Lüscher TF, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011–2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014;64(9):875–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64(2):172–81.CrossRefPubMedGoogle Scholar
  32. 32.
    De Backer O, Piazza N, Banai S, Lutter G, Maisano F, Herrmann HC, et al. Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation. Circ: Cardiovasc Interv. 2014;7(3):400–9.Google Scholar
  33. 33.
    Cheung A, Webb JG, Barbanti M, Freeman M, Binder RK, Thompson C, et al. 5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. J Am Coll Cardiol. 2013;61(17):1759–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Montreal Heart InstituteMontréalCanada

Personalised recommendations